Systematic symptom management in the IMPACT Consortium: rationale and design for 3 effectiveness-implementation trials.
Ashley Wilder SmithLisa DiMartinoSofia F GarciaSandra A MitchellKathryn J RuddyJustin D SmithSandra L WongSeptember CahueDavid CellaRoxanne E JensenMichael J HassettChristine HodgdonBarbara KronerRaymond U OsarogiagbonJennifer PopovicKimberly RichardsonDeborah SchragAndrea L Chevillenull nullPublished in: JNCI cancer spectrum (2023)
Cancer and its treatment produce deleterious symptoms across the phases of care. Poorly controlled symptoms negatively affect quality of life and result in increased health-care needs and hospitalization. The Improving the Management of symPtoms during And following Cancer Treatment (IMPACT) Consortium was created to develop 3 large-scale, systematic symptom management systems, deployed through electronic health record platforms, and to test them in pragmatic, randomized, hybrid effectiveness and implementation trials. Here, we describe the IMPACT Consortium's conceptual framework, its organizational components, and plans for evaluation. The study designs and lessons learned are highlighted in the context of disruptions related to the COVID-19 pandemic.
Keyphrases
- healthcare
- electronic health record
- randomized controlled trial
- primary care
- quality improvement
- systematic review
- squamous cell carcinoma
- double blind
- open label
- young adults
- papillary thyroid
- health insurance
- pain management
- patient reported
- affordable care act
- health information
- combination therapy
- smoking cessation
- chronic pain
- phase ii
- replacement therapy